Treatment of Liver Cell Adenoma in Women with a Hepatic Adenoma 5 cm or Larger

Female patients with a liver cell adenoma (HCA) measuring 5 cm or larger represent a specific clinical population requiring a structured, stepwise management approach.

Clinical scenario: This protocol is specific to female sex with a hepatic adenoma at or above 5 cm. Management centres on modifying relevant risk factors — including cessation of exogenous hormone use — followed by a defined observation period. The course of the lesion during observation directly informs the next decision point, with resection as a key consideration if adequate regression does not occur.

Intervention approach: For patients who are not candidates for resection, an interventional option targeting the adenoma — such as embolization — may be part of the management pathway. The full decision algorithm, indications, and sequencing are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000002857

For females with HCAs that are 5 cm or larger, a period of 6 months of observation is reasonable with cessation of exogenous hormone use (OCPs, hormonal intrauterine devices, and anabolic steroids) and, if applicable, a recommendation for weight loss.

Women with hepatic adenomas ≥5 cm should modify risk factors, undergo observation for 6–12 months, and undergo resection if the lesion does not regress to <5 cm.

If the patient is not a resection candidate, other treatment options should be considered such as embolization.

View source ↗